Long-term effects of s-KL treatment in wild-type mice: Enhancing longevity, physical well-being, and neurological resilience

Abstract

Klotho; Anti-aging; Sarcopenia

Klotho; Antienvelliment; Sarcopènia

Klotho; Antienvejecimiento; Sarcopenia

Aging is a major risk factor for pathologies including sarcopenia, osteoporosis, and cognitive decline, which bring suffering, disability, and elevated economic and social costs. Therefore, new therapies are needed to achieve healthy aging. The protein Klotho (KL) has emerged as a promising anti-aging molecule due to its pleiotropic actions modulating insulin, insulin-like growth factor-1, and Wnt signaling pathways and reducing inflammatory and oxidative stress. Here, we explored the anti-aging potential of the secreted isoform of this protein on the non-pathological aging progression of wild-type mice. The delivery of an adeno-associated virus serotype 9 (AAV9) coding for secreted KL (s-KL) efficiently increased the concentration of s-KL in serum, resulting in a 20% increase in lifespan. Notably, KL treatment improved physical fitness, related to a reduction in muscle fibrosis and an increase in muscular regenerative capacity. KL treatment also improved bone microstructural parameters associated with osteoporosis. Finally, s-KL-treated mice exhibited increased cellular markers of adult neurogenesis and immune response, with transcriptomic analysis revealing induced phagocytosis and immune cell activity in the aged hippocampus. These results show the potential of elevating s-KL expression to simultaneously reduce the age-associated degeneration in multiple organs, increasing both life and health span.

This work was financed by MICINN/AEI/10.13039/501100011033 (PID2022-14624OB-100 and PID2019-104034RB-100 to M.C.) and (PID2023-148834OB-I00) to A.B.; by the Instituto de Salud Carlos III and NexGenerationEU (RICORS, RD21/0017/0008) to M.C. and A.B.; and Generalitat de Catalunya (2021SGR-00529) to A.B. and M.C.